Electron News and Research

RSS

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

SARS-CoV-2 saliva testing that omits the RNA extraction step

Even as the COVID-19 pandemic progresses throughout the world, the lack of consistent diagnostic testing has been a bugbear, preventing public health control of the spread of infection. A new study by researchers at the University of Illinois Urbana-Champaign and published on the preprint server bioRxiv in June 2020 reports a new testing method that uses saliva, does not require RNA extraction, and can be scaled up quickly and inexpensively.

21 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

Direct structural link between SARS-CoV-2 and essential fatty acid

Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.

21 Jun 2020

Characterizing "re-positives" in recovered COVID-19 patients

The novel coronavirus pandemic has been spreading silently or explosively in almost every country of the world, causing almost half a million deaths and nearly 8.5 million reported cases in just six months. While much is known about the virus and the illness by now, far more remains unclear. One such is the prevalence and persistence of antiviral immunity following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

19 Jun 2020

Blood types and COVID-19 risk confirmed

Blood type may play a pivotal role in driving disease severity among coronavirus disease (COVID-19) patients. Genetic analysis of COVID-19 patients has shown that people with blood type O seemed to be protected against severe disease. In contrast, those with blood type A may experience complications tied to the viral infection.

18 Jun 2020

Widespread testing could help stop the spread of COVID-19

The world is now in the grips of a historic pandemic. The death toll from the novel coronavirus has climbed to more than 117,000 in the United States and 448,000 around the world.

18 Jun 2020

Study paints clear picture of how a protein that calms brain activity works

As the body goes about its daily business, molecules called neurotransmitters control the level of electrical activity within the brain.

17 Jun 2020

Globally, 350 million could be at risk of severe COVID-19 and hospitalization

Now, a new study shows that one in five individuals is at risk of getting a severe case of COVID-19 due to the presence of underlying disease. The study appeared in the latest issue of The Lancet Global Health this week.

17 Jun 2020

NIST updates its database of chemical fingerprints

The National Institute of Standards and Technology has updated its database of chemical fingerprints, called mass spectra, that are used to identify unknown chemical compounds.

17 Jun 2020

Can a toilet flush spread coronavirus?

A new study by Chinese researchers at Yangzhou University shows how fluid dynamics can predict if flushing a toilet with the lid open could lead to the transmission of a virus. The study titled, “Can a toilet promote virus transmission? From a fluid dynamics perspective,” was published in the latest issue of the journal, The Journal of Acoustical Society of America (JASA).

17 Jun 2020

Highly conserved RNA structures are essential for SARS-CoV-2 replication and pathogenesis

A recent study from the University of North Carolina at Chapel Hill revealed how selective pressure helps in preserving secondary RNA structures in coronavirus genomes, unveiling a pivotal role of these elements in viral replication and pathogenesis. The paper is currently available on the bioRxiv* preprint server.

17 Jun 2020

Novel ACE2-antibody fusion molecules show anti-SARS-CoV-2 activity

Now, in a new study published on the preprint server, bioRxiv researchers in the U.S. investigated a soluble version of ACE2 for SARS-CoV-2 viral neutralization activity.

17 Jun 2020

Antibiotic X-206 effective against SARS-CoV-2 in vitro

The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.

16 Jun 2020

How antibodies neutralize SARS-CoV-2 in convalescent patients

A new study by researchers from the United Kingdom and Taiwan and published on the preprint server bioRxiv in June 2020 describes the structural basis for the neutralizing effect of the SARS-CoV-2 antibody on the virus. This also indicates a possible therapeutic molecule by identifying its binding epitope as possibly a major neutralizing site.

16 Jun 2020

Scientists evaluate SARS-CoV-2 infection risks in livestock, poultry, pets and wildlife

A large-scale single-cell screening endeavor on a wide variety of animals showed that cells targeted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are most abundant in cats, but are also found in other animals – unveiling a valuable resource for controlling the ongoing disruptive coronavirus disease (COVID-19) pandemic.

16 Jun 2020

Antidepressant fluoxetine (Prozac) suppresses replication of SARS-CoV-2

A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.

16 Jun 2020

New $26.9 million project aims to create better psychiatric drugs without side effects

Rapidly acting drugs to treat depression, anxiety, or substance abuse without side effects do not exist. Researchers led by Bryan L. Roth, MD, PhD, the Michael Hooker Distinguished Professor of Pharmacology at the UNC School of Medicine, are trying to change that.

16 Jun 2020

Tracing coronavirus habitats with genomics

Now, a new study by researchers at the University of Ottawa and published on the preprint server bioRxiv in June 2020 reports the differences in genomes of viruses that are exposed to antiviral proteins vs. those that are not. This host-derived pressure on the virus to adapt may help devise newer ways to build an effective vaccine.

15 Jun 2020